glp-1 drugs and autoimmune disease Lower Risk of Death by 44% in Obesity Why are GLP-1 agonists being

doi: 10.3168/JDS.2008-1769 131 WallaceH

Jardiance family Disease area(s): Metabolic/cardiovascular Manufacturer(s): Boehringer Ingelheim/Eli Lilly and Company 2024 Sales (USD): $12.38 billion Why it sold so well: Co-developed by Boehringer Ingelheim and Eli Lilly, the Jardiance family experienced robust growth in 2024, driven by expanding clinical indications and strong global demand

We used Image J ( and the Leica software to analyze the data

High prevalence of malnutrition and micronutrient deficiencies in patients with inflammatory bowel disease early in disease course

Last updated December 2020

The body cannot simply "flush" a fat-soluble toxin